Tatsis Ourania

EVP Tatsis Ourania sold 4,500 shares of VRTX at $474.99 (2026-01-07) for $2.1M; retains 42.3K shares. Mixed track record at this ticker.

Tatsis Ourania, EVP Chief Regulatory & Quality Officer, sold 4,500 shares for $2,137,455.00 at a price of $474.99, reducing holdings by 9.6% to 42,293 shares. The sale occurred near the 52-week high (current price $463.86 is 9.7% below the $513.76 peak), which might appear tactically favorable. However, her prior trade history at VRTX provides a cautionary signal: of 5 previous sales at this ticker, outcomes at the 90-day mark were mixed—2 of 4 measurable trades were well-timed (negative returns after the sale), while the other 2 saw positive returns, indicating the insider has not demonstrated consistent predictive accuracy when selling this stock. Her cross-ticker track record shows an average 90-day return of +3.5% after sells and a 33.33% well-timed rate, which is below 50% and suggests her prior sells have generally been poorly timed across her broader activity. This transaction warrants observation to determine whether it aligns with the unfavorable pattern observed in her VRTX-specific history.

EVP Tatsis Ourania sold 4,500 VRTX shares at $449.99 on 2025-12-03 for $2,024,955.00.

Tatsis Ourania, Executive Vice President and Chief Regulatory & Quality Officer, sold 4,500 shares (−8.8% of pre-transaction holdings) at $449.99, reducing her position from 51,293 to 46,793 shares. The sale occurred 11.3% below the 52-week high of $513.76, while the stock has gained 9.2% over the preceding 30 days and 15.0% over 90 days. Across her cross-ticker open-market history, her 6 prior sells averaged a 3.5% 90-day gain (poorly timed, as the stock rose after her sales), with only a 33.33% well-timed rate. Specifically at VRTX, 2 of her 5 prior sales were well-timed, and her most recent VRTX sales in March 2025 resulted in 90-day declines of −9.9% and −8.2%, though earlier 2024 sales saw substantial 90-day gains of +10.9% and +11.5%. The company's fundamentals show strong performance: revenue of $3,076,400,000.00 in the latest quarter with 11.7% annual growth, and current-quarter net income of $1,082,900,000.00, though full-year net income is negative—creating a contrast between quarterly profitability and annual loss.

EVP Ourania sold 3,242 shares of VRTX at $499.99 on 2025-03-10, retaining 51,239 shares (-6.0% of holdings)

Tatsis Ourania, EVP of Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, executed a discretionary open-market sale of 3,242 shares at $499.99 on 2025-03-10, reducing holdings from 54,481 to 51,239 shares. This transaction represents a modest portfolio reduction of -6.0% and occurs 6 days after another sale at the same ticker on 2025-03-04, suggesting recent liquidity activity. Vertex fundamentals show strong operating performance: $2.8B quarterly revenue with +11.7% annual growth and $1.0B net income in the latest period, though the full fiscal year was unprofitable. At the transaction price of $499.99, the insider sold near the 52-week high of $516.74 (-4.1%), while the current price sits at $495.42 (+5.4% over 30 days). Reviewing Ourania's prior sales at VRTX: among 4 completed trades with measurable outcomes, none were well-timed at the 90-day mark (all showed positive 90-day returns ranging +7.8% to +11.5%), indicating the stock consistently rose after prior sales. This pattern, combined with the sale at near-peak valuation, warrants tracking to assess whether current execution aligns with or deviates from historical outcomes at this ticker.

EVP Tatsis Ourania sold 4,058 shares of VRTX at $485.49 on 2025-03-04 for $1,970,118.42; holdings reduced to 54,481 shares.

Ourania, Chief Regulatory & Quality Officer, sold 4,058 shares (4.1K shares) worth $1,970,118.42 at $485.49 per share, reducing holdings by 6.9% to 54,481 shares. The timing context shows mixed signals: at her prior trades at VRTX, 0 of 4 sells were well-timed at the 90-day mark—all were followed by gains ranging from +7.8% to +11.5%, meaning she systematically sold before subsequent appreciation. Her cross-ticker track record shows an avg 90d return of +9.8% after sells with a 0.00% well-timed rate, reinforcing a pattern of selling ahead of rallies rather than declines. Vertex is a $124.7B market-cap pharmaceutical firm with positive operating quarterly results ($1.0B net income on $2.8B revenue) but a negative full-year net income, suggesting earnings volatility that may warrant monitoring of insider confidence signals.